Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 8:15:1355412.
doi: 10.3389/fphar.2024.1355412. eCollection 2024.

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices

Lucas Pereira  1   2 , Cyrine-Eliana Haidar  3 , Susanne B Haga  4 , Anna G Cisler  5 , April Hall  2   6 , Sanjay K Shukla  1 , Scott J Hebbring  1 , Emili J W Leary  1
Affiliations

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices

Lucas Pereira et al. Front Pharmacol. .

Abstract

Introduction: The practice of informed consent (IC) for pharmacogenomic testing in clinical settings varies, and there is currently no consensus on which elements of IC to provide to patients. This study aims to assess current IC practices for pharmacogenomic testing. Methods: An online survey was developed and sent to health providers at institutions that offer clinical germline pharmacogenomic testing to assess current IC practices. Results: Forty-six completed surveys representing 43 clinical institutions offering pharmacogenomic testing were received. Thirty-two (74%) respondents obtain IC from patients with variability in elements incorporated. Results revealed that twenty-nine (67%) institutions discuss the benefits, description, and purpose of pharmacogenomic testing with patients. Less commonly discussed elements included methodology and accuracy of testing, and laboratory storage of samples. Discussion: IC practices varied widely among survey respondents. Most respondents desire the establishment of consensus IC recommendations from a trusted pharmacogenomics organization to help address these disparities.

Keywords: clinical implementation; genetic counseling; genetic testing; informed consent; pharmacogenetics; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Survey responses by institution.
FIGURE 2
FIGURE 2
States within the United States with a clinical pharmacogenomic respondent institution in purple. Created with MapChart.
FIGURE 3
FIGURE 3
Institutions’ IC practices by age demographic (n = 43).
FIGURE 4
FIGURE 4
Major barriers for pharmacogenomic testing education/informed consent (n = 36). *Respondents may mark multiple options or not indicate the extent to which the barrier prevents them from obtaining IC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Almazroo O. A., Miah M. K., Venkataramanan R. (2017). Drug metabolism in the liver. Clin. Liver Dis. 21 (1), 1–20. 10.1016/j.cld.2016.08.001 - DOI - PubMed
    1. Accreditation Council for Genetic Counseling (2003). Practice-Based Competencies for Genetic Counselors. McLean, VA, August, 31.
    1. Althubaiti A. (2016). Information bias in health research: definition, pitfalls, and adjustment methods. J. Multidiscip. Healthc. 9 (9), 211–217. 10.2147/JMDH.S104807 - DOI - PMC - PubMed
    1. AMA (2013). AMA code of medical ethics’ opinion on informing patients about treatment options. AMA J. Ethics 15 (1), 28. 10.1001/virtualmentor.2013.15.1.coet1-1301 - DOI
    1. Ando Y., Terada T. (2023). Consent in pharmacogenetic testing. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 41 (22), 3875. 10.1200/JCO.23.00664 - DOI - PubMed

LinkOut - more resources